Vasoactive peptides as biomarkers for the prediction of retinopathy of prematurity.

Journal

Pediatric research
ISSN: 1530-0447
Titre abrégé: Pediatr Res
Pays: United States
ID NLM: 0100714

Informations de publication

Date de publication:
24 Feb 2024
Historique:
received: 02 08 2023
accepted: 28 01 2024
revised: 27 12 2023
medline: 25 2 2024
pubmed: 25 2 2024
entrez: 24 2 2024
Statut: aheadofprint

Résumé

Retinopathy of prematurity (ROP) is a major complication in preterm infants. We assessed if plasma levels of midregional pro-atrial natriuretic peptide (MR-proANP) and C-terminal pro-endothelin-1 (CT-proET1) serve as early markers for subsequent ROP development in preterm infants <32 weeks gestation. Prospective, two-centre, observational cohort study. MR-proANP and CT-proET1 were measured on day seven of life. Associations with ROP ≥ stage II were investigated by univariable and multivariable logistic regression models. We included 224 infants born at median (IQR) 29.6 (27.1-30.8) weeks gestation and birth weight of 1160 (860-1435) g. Nineteen patients developed ROP ≥ stage II. MR-proANP and CT-proET1 levels were higher in these infants (median (IQR) 864 (659-1564) pmol/L and 348 (300-382) pmol/L, respectively) compared to infants without ROP (median (IQR) 299 (210-502) pmol/L and 196 (156-268) pmol/L, respectively; both P < 0.001). MR-proANP and CT-proET1 levels were significantly associated with ROP ≥ stage II in univariable logistic regression models and after adjusting for co-factors, including gestational age and birth weight z-score. MR-proANP and CT-proET1 measured on day seven of life are strongly associated with ROP ≥ stage II in very preterm infants and might improve early prediction of ROP in the future. Plasma levels of midregional pro-atrial natriuretic peptide and C-terminal pro-endothelin-1 measured on day seven of life in very preterm infants show a strong association with development of retinopathy of prematurity ≥ stage II. Both biomarkers have the potential to improve early prediction of retinopathy of prematurity. Vasoactive peptides might allow to reduce the proportion of screened infants substantially.

Sections du résumé

BACKGROUND BACKGROUND
Retinopathy of prematurity (ROP) is a major complication in preterm infants. We assessed if plasma levels of midregional pro-atrial natriuretic peptide (MR-proANP) and C-terminal pro-endothelin-1 (CT-proET1) serve as early markers for subsequent ROP development in preterm infants <32 weeks gestation.
METHODS METHODS
Prospective, two-centre, observational cohort study. MR-proANP and CT-proET1 were measured on day seven of life. Associations with ROP ≥ stage II were investigated by univariable and multivariable logistic regression models.
RESULTS RESULTS
We included 224 infants born at median (IQR) 29.6 (27.1-30.8) weeks gestation and birth weight of 1160 (860-1435) g. Nineteen patients developed ROP ≥ stage II. MR-proANP and CT-proET1 levels were higher in these infants (median (IQR) 864 (659-1564) pmol/L and 348 (300-382) pmol/L, respectively) compared to infants without ROP (median (IQR) 299 (210-502) pmol/L and 196 (156-268) pmol/L, respectively; both P < 0.001). MR-proANP and CT-proET1 levels were significantly associated with ROP ≥ stage II in univariable logistic regression models and after adjusting for co-factors, including gestational age and birth weight z-score.
CONCLUSIONS CONCLUSIONS
MR-proANP and CT-proET1 measured on day seven of life are strongly associated with ROP ≥ stage II in very preterm infants and might improve early prediction of ROP in the future.
IMPACT CONCLUSIONS
Plasma levels of midregional pro-atrial natriuretic peptide and C-terminal pro-endothelin-1 measured on day seven of life in very preterm infants show a strong association with development of retinopathy of prematurity ≥ stage II. Both biomarkers have the potential to improve early prediction of retinopathy of prematurity. Vasoactive peptides might allow to reduce the proportion of screened infants substantially.

Identifiants

DOI: 10.1038/s41390-024-03091-w PMID: 38402317
pubmed: 38402317
doi: 10.1038/s41390-024-03091-w
pii: 10.1038/s41390-024-03091-w
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s).

Références

Hellström, A., Smith, L. E. & Dammann, O. Retinopathy of prematurity. Lancet 382, 1445–1457 (2013).
doi: 10.1016/S0140-6736(13)60178-6 pubmed: 23782686 pmcid: 4389630
Fierson, W. M. & Capone, A. Jr., American Academy of Pediatrics Section on Ophthalmology, American Academy of Ophthalmology, American Association of Certified Orthoptists. Telemedicine for evaluation of retinopathy of prematurity. Pediatrics 135, e238–e254 (2015).
doi: 10.1542/peds.2014-0978 pubmed: 25548330
Wade, K. C. et al. Safety of retinopathy of prematurity examination and imaging in premature infants. J. Pediatr. 167, 994–1000.e1002 (2015).
doi: 10.1016/j.jpeds.2015.07.050 pubmed: 26299381 pmcid: 4661087
Gerull, R. et al. Incidence of Retinopathy of Prematurity (ROP) and ROP treatment in Switzerland 2006–2015: a population-based analysis. Arch. Dis. Child Fetal Neonatal Ed. 103, F337–F342 (2018).
doi: 10.1136/archdischild-2017-313574 pubmed: 28916563
Bührer, C. et al. N-terminal B-type natriuretic peptide urinary concentrations and retinopathy of prematurity. Pediatr. Res. 82, 958–963 (2017).
doi: 10.1038/pr.2017.179 pubmed: 28738027
Gerull, R. et al. Prediction of ROP treatment and evaluation of screening criteria in VLBW infants—a population-based analysis. Pediatr. Res. 84, 632–638 (2018).
doi: 10.1038/s41390-018-0128-3 pubmed: 30188497
Poppe, J. A. et al. Early prediction of severe retinopathy of prematurity requiring laser treatment using physiological data. Pediatr. Res. 94, 699–706 (2023).
Rollin, R., Mediero, A., Roldan-Pallares, M., Fernandez-Cruz, A. & Fernandez-Durango, R. Natriuretic peptide system in the human retina. Mol. Vis. 10, 15–22 (2004).
pubmed: 14737067
Morgenthaler, N. G., Struck, J., Thomas, B. & Bergmann, A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin. Chem. 50, 234–236 (2004).
doi: 10.1373/clinchem.2003.021204 pubmed: 14709661
Marasciulo, F. L., Montagnani, M. & Potenza, M. A. Endothelin-1: the Yin and Yang on vascular function. Curr. Med Chem. 13, 1655–1665 (2006).
doi: 10.2174/092986706777441968 pubmed: 16787211
Patel, C. et al. Activation of the endothelin system mediates pathological angiogenesis during ischemic retinopathy. Am. J. Pathol. 184, 3040–3051 (2014).
doi: 10.1016/j.ajpath.2014.07.012 pubmed: 25203536 pmcid: 4215027
Papassotiriou, J., Morgenthaler, N. G., Struck, J., Alonso, C. & Bergmann, A. Immunoluminometric assay for measurement of the c-terminal endothelin-1 precursor fragment in human plasma. Clin. Chem. 52, 1144–1151 (2006).
doi: 10.1373/clinchem.2005.065581 pubmed: 16627560
Gerull, R. et al. Respiratory morbidity in preterm infants predicted by natriuretic peptide (MR-proANP) and endothelin-1 (CT-proET-1). Pediatr. Res. 91, 1478–1484 (2022).
doi: 10.1038/s41390-021-01493-8 pubmed: 33958715
International Committee for the Classification of Retinopathy of Prematurity. The international classification of retinopathy of prematurity revisited. Arch. Ophthalmol. 123, 991–999 (2005).
doi: 10.1001/archopht.123.7.991
Czernik, C., Metze, B., Muller, C., Muller, B. & Bührer, C. Urinary N-terminal B-type natriuretic peptide predicts severe retinopathy of prematurity. Pediatrics 128, e545–e549 (2011).
doi: 10.1542/peds.2011-0603 pubmed: 21824875
Ding, W. et al. A good way to reduce screening for retinopathy of prematurity: development of the ROP model in a China preterm population. Front. Pediatr. 9, 697690 (2021).
doi: 10.3389/fped.2021.697690 pubmed: 34277525 pmcid: 8278052
Edwards, B. S., Zimmerman, R. S., Schwab, T. R., Heublein, D. M. & Burnett, J. C. Jr. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ. Res. 62, 191–195 (1988).
doi: 10.1161/01.RES.62.2.191 pubmed: 2962782
Kotby, A. A. et al. Atrial natriuretic peptide as a marker of heart failure in children with left ventricular volume overload. J. Paediatr. Child Health 49, 43–47 (2013).
doi: 10.1111/jpc.12012 pubmed: 23279037
Grass, B. et al. Cardiovascular biomarkers pro-atrial natriuretic peptide and pro-endothelin-1 to monitor ductus arteriosus evolution in very preterm infants. Early Hum. Dev. 90, 293–298 (2014).
doi: 10.1016/j.earlhumdev.2014.03.002 pubmed: 24661445
Rosenberg, A. A. et al. Elevated immunoreactive endothelin-1 levels in newborn infants with persistent pulmonary hypertension. J. Pediatr. 123, 109–114 (1993).
doi: 10.1016/S0022-3476(05)81552-5 pubmed: 8320603
Benzing, J. et al. Plasma pro-endothelin-1 and respiratory distress in newborn infants. J. Pediatr. 160, 517–519 (2012).
doi: 10.1016/j.jpeds.2011.10.011 pubmed: 22099523
Letzner, J. et al. Plasma C-terminal pro-endothelin-1 and the natriuretic pro-peptides NT-proBNP and MR-proANP in very preterm infants with patent ductus arteriosus. Neonatology 101, 116–124 (2012).
doi: 10.1159/000330411 pubmed: 21952518
Spiranec Spes, K. et al. Natriuretic peptides attenuate retinal pathological neovascularization via cyclic guanosine monophosphate signaling in pericytes and astrocytes. Arterioscler. Thromb. Vasc. Biol. 40, 159–174 (2020).
doi: 10.1161/ATVBAHA.119.313400 pubmed: 31619060
Lara-Castillo, N. et al. Atrial natriuretic peptide reduces vascular leakage and choroidal neovascularization. Am. J. Pathol. 175, 2343–2350 (2009).
doi: 10.2353/ajpath.2009.090439 pubmed: 19910509 pmcid: 2789643
Jung, J. L. et al. Validation of Winrop for detecting retinopathy of prematurity in a North American cohort of preterm infants. J. AAPOS 21, 229–233 (2017).
doi: 10.1016/j.jaapos.2017.05.004 pubmed: 28506724
Binenbaum, G., Ying, G. S., Tomlinson, L. A. & Postnatal, G., Retinopathy of Prematurity Study, G. Validation of the Children’s Hospital of Philadelphia Retinopathy of Prematurity (CHOP ROP) model. JAMA Ophthalmol. 135, 871–877 (2017).
doi: 10.1001/jamaophthalmol.2017.2295 pubmed: 28715553 pmcid: 5710287
Eckert, G. U., Fortes Filho, J. B., Maia, M. & Procianoy, R. S. A predictive score for retinopathy of prematurity in very low birth weight preterm infants. Eye 26, 400–406 (2012).
doi: 10.1038/eye.2011.334 pubmed: 22193874
Desai, S., Athikarisamy, S. E., Lundgren, P., Simmer, K. & Lam, G. C. Validation of Winrop (Online Prediction Model) to identify severe retinopathy of prematurity (ROP) in an Australian preterm population: a retrospective study. Eye 35, 1334–1339 (2021).
doi: 10.1038/s41433-020-1094-7 pubmed: 32681095
Sun, H. et al. Using ROPScore and CHOP ROP for early prediction of retinopathy of prematurity in a Chinese population. Ital. J. Pediatr. 47, 39 (2021).
doi: 10.1186/s13052-021-00991-z pubmed: 33602298 pmcid: 7890862
Thomas, D. et al. Diagnostic Accuracy of WINROP, CHOP-ROP and ROPScore in Detecting Type 1 Retinopathy of Prematurity. Indian Pediatr. 58, 915–921 (2021).
doi: 10.1007/s13312-021-2321-4 pubmed: 34016801 pmcid: 8549580

Auteurs

Roland P Neumann (RP)

Department of Neonatology, University Children's Hospital Basel UKBB, University of Basel, Basel, Switzerland. rolandp.neumann@ukbb.ch.

Roland Gerull (R)

Department of Neonatology, University Children's Hospital Basel UKBB, University of Basel, Basel, Switzerland.
Division of Neonatology, University Children's Hospital Inselspital Berne, Berne, Switzerland.

Pascal W Hasler (PW)

Department of Ophthalmology, University Hospital Basel, Basel, Switzerland.

Sven Wellmann (S)

Department of Neonatology, University Children's Hospital Regensburg (KUNO), Hospital St. Hedwig of the Order of St. John, University of Regensburg, Regensburg, Germany.

Sven M Schulzke (SM)

Department of Neonatology, University Children's Hospital Basel UKBB, University of Basel, Basel, Switzerland.

Classifications MeSH